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Background: Rodent models of acute ischaemic stroke and head injury suggest that apolipoprotein E
(APOE) genotype influences neuronal repair, regeneration and survival after brain injury. Possession of an
APOE e4 allele is associated with poor outcome after head injury in clinical studies. APOE might therefore
influence outcome after acute stroke in humans.
Objective and methods: To comprehensively search, identify, assess and carry out meta-analyses of
studies reporting on the association between APOE and the combined outcome of death or dependency,
or death alone, several months after ischaemic stroke, intracerebral haemorrhage (ICH) or subarachnoid
haemorrhage (SAH).
Results: Main analyses included data from nine studies on 2262 patients (1453 with ischaemic stroke, 199
with ICH and 610 with SAH). Overall, e4+ genotypes were not significantly associated with risk of death or
dependency several months after stroke. However, there was significant heterogeneity between studies,
and between the three pathological types of stroke. e4+ genotypes were associated with increased death
or dependency after SAH (relative risk (RR) 1.40, 95% confidence interval (CI) 1.06 to 1.84), with a trend
towards a similar association with ICH (RR 1.38, 95% CI 0.99 to 1.92), but not with ischaemic stroke (RR
0.98, 95% CI 0.85 to 1.12). Results were similar for death alone.
Conclusions: APOE may differentially affect outcome after the three main pathological types of stroke.
Further, large studies are needed to confirm or refute these findings, and to assess the possibility of an
interaction between the effects of APOE and age.
I
n contrast with the many studies assessing the role of
various candidate genes in the causation of stroke and its
subtypes,1–3 the role of genetic factors influencing outcome
after acute stroke has been relatively little studied in
humans.4 5 However, studies on animal models of stroke
comparing outcomes among genetically manipulated animals
with those among wild-type animals suggest that this should
be a promising subject, which may ultimately improve our
understanding of the pathways of neuronal protection and
recovery, and even lead to new therapeutic insights.4 6
The apolipoprotein E gene (APOE) is one of the most
widely studied genes in vascular and neurodegenerative
diseases. Its protein product is a 34-kDa glycoprotein with
three common isoforms, E2, E3 and E4, encoded by the
alleles e2, e3 and e4, respectively, giving rise to six genotypes,
the e3/e3 genotype occurring in about 50–66% of people in
most populations.7 APOE has a major role in lipid redistribu-
tion, which is important for membrane maintenance and
repair in the brain, and in the regulation of synaptic
remodelling during or after brain injury.6 8–11 Rodent models
of head injury and ischaemic stroke suggest that APOE
influences neuronal repair, regeneration and survival after
brain injury.6 11 In clinical studies, possession of an APOE e4
allele is associated with poor outcome after head injury.5
These observations suggest that APOE might influence
outcome after acute stroke in humans, but clinical studies
have produced conflicting results.5
Here, we use systematic review and meta-analysis methods to
assess the effect of APOE on outcome after the three main
pathological types of acute stroke: ischaemic stroke, intracerebral
haemorrhage (ICH) and subarachnoid haemorrhage (SAH).
METHODS
Study identification and selection
We sought all available published studies on the influence of
APOE on outcome (death or the combination of death or
dependency) after acute stroke in adult humans. We
identified studies by searching Medline and Embase from
1966 to May 2005 (search strategy in box 1), the reference
lists of relevant papers thus identified and recent textbooks
on stroke or stroke genetics. We included only studies that
analysed the main pathological stroke types separately. For
studies with more than one publication describing results on
overlapping groups of patients, we included only the largest
of the available published datasets to avoid double counting.
We requested summary data from the authors of two studies
for which relevant data had been obtained but were not
reported in the publications. We independently selected
relevant studies, resolving disagreements by discussion.
Data extraction
From each study selected, we extracted information on year
of publication; setting and country; subjects’ ethnicity;
number of subjects; definition of acute stroke; whether or
not recruitment was consecutive; subjects’ mean age and sex
distribution; method, definition and timing of outcome
assessment; blinding of genotyping to outcome assessment,
and of outcome assessors to genotype; and genotyping
samples and methods. We extracted data on the numbers
of subjects who had died or were dead or dependent at the
Abbreviations: APOE, apolipoprotein E gene; ICH, intracerebral
haemorrhage; SAH, subarachnoid haemorrhage
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end of follow-up with genotypes containing or not containing
the e4 allele (e4+ genotypes), and with or without the e2+
genotype. We independently extracted the information from
each study, resolving disagreements by discussion.
Statistical analyses
We assessed the effects of e4+ versus e42 genotypes (primary
analysis) and those of e2+ versus e22 genotypes (secondary
analysis) on death and death or dependency by calculating
study-specific and fixed effects pooled relative risks (RRs)
using Cochrane RevMan software (V.4.2; http://www.cc-ims.
net/RevMan). We used the x2 test to assess heterogeneity
between studies and different pathological types of stroke.
As data from two eligible studies were unavailable and so
excluded from our main analyses (see below), we carried out
sensitivity analyses for the e4+ versus e42 comparison to
assess what effect a range of plausible results for these
studies might have had on our conclusions (additional data
are available online at http://www.jnnp.bmjjjournals.com/
supplemental).
RESULTS
Characteristics of included studies
The 949 articles identified by our search yielded 18 potentially
relevant papers,12–29 from which we selected 11 eligible
studies on 3120 subjects.12–22 We had to exclude two of these
from our main analyses, as outcome data that had been
collected were unavailable in the publications, and the
authors could not provide us with unpublished summary
data.14 16 Thus, we included nine studies on 2262 subjects in
our main analyses (fig 1). Table 1 summarises the details.
The studies were mainly conducted in European countries
on white people, but one in the USA was conducted on
Caucasians and African Americans,17 and two were on
Chinese patients.18 21 All were hospital based. Six studies
recruited consecutively admitted patients,13 14 18–20 22 one
recruited patients from a randomised trial of thrombolysis
for acute ischaemic stroke (ie, highly selected patients),15 two
stated that the patients were ‘‘unselected’’,12 16 and two did
not state whether recruitment was consecutive or in some
way selective.17 21
Genotype and outcome data were available for 1898 of the
2262 (84%) subjects from the nine studies in our main
analyses. All had data on e4+ genotypes, whereas only five
had data on e2+ genotypes.13 15 17 21 22 One study included
both IS and ICH patients.12 Mean age was 69 years in the IS
patients, 68 years in the ICH patients, and 51 years in the
SAH patients. Around half of the patients were male.
Eight of the nine studies in the main analyses provided
data on the combined outcome of death or dependency,
defined on the basis of the Glasgow Outcome Scale in the five
studies on SAH,18–22 discharge to an institution in one study,12
the modified Rankin Scale and the Barthel index in one
study,13 and the modified Rankin Scale, Barthel index,
Glasgow Outcome Scale and National Institutes of Health
Stroke Scale in another.15 We used the modified Rankin Scale
data for our analyses for these last two studies. Only four of
the nine studies in the main analyses presented data
separately on death.13 14 17 19 Outcomes were assessed at
3 months in five studies,12 13 15 21 22 at 6 months in three
949 papers identified
by search
18 potentially relevant
papers12–29
11 eligible studies12–22
3120 patients
2251 with IS, 259 with ICH,
610 with SAH
9 studies with data for main
analyses12,13,15,17–22
2262 patients
1453 with IS, 199 with ICH, 
610 with SAH
Review of titles, abstracts or full papers
Exclusions:
4 papers
describing results
from patients
already included in
another paper23–26
3 studies with
highly selective
inclusion
dependent on early
survival27–29
2 eligible studies
without available data
excluded from main
analyses14,16
858 patients
798 with IS, 60 with ICH
Figure 1 Selection of studies for inclusion.
Box 1: Search strategy for Medline
1. apolipoproteins/ or apolipoproteins e/
2. ((apolipoprotein$ adj e) or (apoprotein$ adj e) or apo-
e or apo e or apoe).tw.
3. ((apolipoprotein$ adj e2) or (apoprotein$ adj e2) or
apo-e2 or apo e2 or apoe2).tw.
4. ((apolipoprotein$ adj e3) or (apoprotein$ adj e3) or
apo-e3 or apo e3 or apoe3).tw.
5. ((apolipoprotein$ adj e4) or (apoprotein$ adj e4) or
apo-e4 or apo e4 or apoe4).tw.
6. ((apolipoprotein$ adj e5) or (apoprotein$ adj e5) or
apo-e5 or apo e5 or apoe5).tw.
7. ((apolipoprotein$ adj e7) or (apoprotein$ adj e7) or
apo-e7 or apo e7 or apoe7).tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp cerebrovascular disorders/ or exp basal ganglia
cerebrovascular disease/ or exp brain ischemia/ or
exp carotid artery diseases/ or exp cerebrovascular
accident/ or exp hypoxia-ischemia, brain/ or exp
intracranial arterial diseases/ or exp ‘‘intracranial
embolism and thrombosis’’/ or exp intracranial hemor-
rhages/ or vasospasm, intracranial/
10. (stroke$ or apoplexy or cerebral vasc$ or cerebrovasc$
or cva$).tw.
11. 9 or 10
12. 8 and 11
13. limit 12 to human
A similar strategy was designed for Embase.
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studies18–20 and at hospital discharge in one study.17 Follow-
up was generally by examination or telephone interview.
Outcomes were assessed blind to genotype and vice versa in
all but one study that did not comment on blinding.17
All studies used blood samples for DNA extraction, and one
also used buccal smears.19 Genotype analysis was by restriction
enzyme digestion of the polymerase chain reaction product in
all but one study, which assessed APOE genotypes indirectly by
measuring the apolipoprotein E protein phenotypes.15
Effects on death or dependency—main analyses
Overall, there was no significant effect of e4+ versus e42
genotypes (summary RR 1.08, 95% confidence interval (CI) 0.96
to 1.21; fig 2). However, there was significant heterogeneity
between the studies (x28 = 25.4, p = 0.001), some of which
seemed to be accounted for by the pathological type of stroke.
We found no significant effect on ischaemic stroke (RR 0.98,
95% CI 0.85 to 1.12), but found a trend towards an association
with poor outcome after ICH (RR 1.38, 95% CI 0.99 to 1.92) and
a significant association with poor outcome after SAH (RR 1.40,
95% CI 1.06 to 1.84). There was significant heterogeneity
between the pooled results for the three pathological types of
stroke (x22 = 10.4, p = 0.005), and residual heterogeneity
between the results of the five studies on SAH (fig 2).
There was no significant effect of e2+ versus e22 genotypes,
either overall or for the pathological types of stroke considered
separately. However, the reliability of these analyses is limited,
as they were based on less than half of the available data.
Effects on death—main analyses
The pattern of the results for e4+ versus e42 genotypes was
similar to that for death or dependency, although less than half
of the total subjects contributed to these analyses. Overall, there
was a just significant increase in the risk of death with an e4+
genotype (RR 1.24, 95% CI 0.92 to 1.67). There was no
significant effect for ischaemic stroke (RR 1.08, 95% CI 0.75
to 1.55), but e4+ genotypes conferred a non-significant trend
towards an increased risk of death for patients with ICH (RR
1.63, 95% CI 0.89 to 2.98) and SAH (RR 1.98, 95% CI 0.72 to
5.49). However, as there was no statistically significant
heterogeneity between results of the individual studies or the
three pathological types of stroke, these subgroup analyses
should be interpreted with caution (fig 3).
Data on the effects of e2+ versus e22 genotypes were
available for only about one third of the available data,
making the reliability of the results limited. There was no
significant effect on death overall or for the separate
pathological types of stroke.
Most studies provided both unadjusted results and results
adjusted for potential confounders of the association between
APOE and outcome. Unadjusted and adjusted results were
generally very similar, although in two of the studies on SAH,
the association of e4+ genotypes with poor outcome became
more extreme after adjustment.18 19
Sensitivity analyses
Tables A and B provided online at http://www.jnnp.bmjjour-
nals.com/supplemental show detailed results. Including
plausible values for the eligible studies with unavailable data
did not affect the results of our meta-analyses of the effect of
e4+ genotypes on outcome after ischaemic stroke.14 16
However, including plausible data for ICH from Catto et al14
produced a range of results, which included the possibilities
of either no effect or an adverse effect on death after
intracerebral haemorrhage.
DISCUSSION
These results suggest that e4 carriers may be at increased risk of
poor outcome (death or dependency, or death alone) several
months after ICH or SAH, but not that after ischaemic stroke.
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Figure 2 Meta-analysis of effect of apolipoprotein E e4+ genotypes on death or dependency several months after acute stroke. n, number dead or
dependent at time of outcome assessment; N, number with specified genotype. Squares represent point estimates of relative risks, with size proportional
to the statistical weight of each study. Horizontal lines correspond to 95% CI. Pooled relative risks are shown as diamonds, whose width is their 95% CI.
Figure 3 Meta-analysis of effect of the apolipoprotein E e4+ genotypes on death several months after acute stroke. n, number who had died by the
time of outcome assessment; N, number with specified genotype. Squares represent point estimates of relative risks, with size proportional to the
statistical weight of each study. Horizontal lines correspond to 95% CI. Pooled relative risks are shown as diamonds, whose width is their 95% CI.
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However, it is important to consider whether the appar-
ently deleterious effect of e4+ genotypes on outcome after
ICH or SAH could be a false-positive finding. Residual
confounding seems unlikely to explain our findings, as
unadjusted and adjusted results were generally similar.
However, various potential sources of bias could lead to
false-positive results. Firstly, publication bias (where the
results of small positive studies are more likely to be
published than those of small negative studies) could explain
why the pooled results of the smaller studies on ICH and SAH
(mean number of subjects 116) were positive, whereas those
of the larger studies on ischaemic stroke (mean number of
subjects 484) were not. Publication bias has often been
identified in systematic reviews of observational epidemiolo-
gical studies,30 including candidate gene studies—for exam-
ple, our own study on the role of APOE in incidence of
different pathological types of stroke.3 Secondly, reporting
bias could have affected our findings, as data on both
outcomes of interest were not available from all studies.
Thirdly, selection and ‘‘loss-to-follow-up’’ biases may have
affected our results because, although several studies
recruited consecutive patients, patients had to survive long
enough to give consent and provide a sample for DNA; the
most severely affected patients with stroke who died early
were inevitably excluded. In addition, outcome data were not
available for all recruited patients, and one study on ICH
reported outcome at discharge from hospital, which may
have introduced bias if time to discharge varied between
APOE genotype groups.17
Could the result of no apparent effect on outcome after
ischaemic stroke be a false-negative finding? This seems less
likely, particularly as two additional eligible studies for which
we were unable to obtain data found no association between
APOE and outcome after ischaemic stroke, and including
plausible values for these in sensitivity analyses did not alter
our findings.14 16 Our meta-analysis of effects on death or
dependency after ischaemic stroke included studies with
varying outcome definitions, but this seems unlikely to have
affected the overall results, as the RRs for the different
studies were similar. Another possibility is that we may have
missed an effect on outcome after ischaemic stroke because
of an interaction with age. The patients in the studies on
ischaemic stroke were slightly older than those with
haemorrhagic stroke, particularly SAH. A recent study found
that the effect of e4+ genotypes on death or severe disability
6 months after acute head injury was age dependent. The
association was most pronounced in participants aged ,15
years and diminished with increasing age.31 This raises the
possibility that an association between the APOE genotype
and outcome after ischaemic stroke might be detectable only
in patients with a mean age at least several years below that
of the ischaemic stroke patients in the studies in our review,
and that the association between APOE genotype and
outcome after ICH or SAH may be stronger with decreasing
age. However, given the small difference in mean age
between the patients with ischaemic stroke, ICH and SAH,
this seems unlikely to be the only reason for the difference in
results between haemorrhagic and ischaemic types of stroke.
The explanation for the apparent differences between the
effects on different pathological types of stroke, if real, is
uncertain. Some studies have suggested that the effects on
SAH might be due to an association of e4+ genotypes with
delayed ischaemic neurological deficit.20 32 A study exploring
the reasons for the association between e4+ genotypes and
poor outcome after ICH found no detectable effect of APOE
on haematoma or oedema volumes.17 Another study that
examined whether the effects of APOE on coagulation
profiles might explain the different effects on outcome after
ischaemic stroke and ICH found inconclusive results.25
In summary, our results suggest that APOE may affect
outcome after ICH and SAH, but not after ischaemic stroke.
Larger studies are needed to confirm or refute these findings,
and to assess the possibility of an interaction between the
effects of the APOE genotype and age. If the apparent
differences between the pathological types of stroke are
confirmed, research into the reasons for this should improve
our understanding of the role of apolipoprotein E in recovery
after stroke, and may ultimately lead to new therapeutic
insights.
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Susac’s syndrome: effective combination of immunosuppression and antiplatelet treatment
S
usac’s syndrome is a rare disease predominantly affect-
ing young women. The syndrome is characterised by the
triad of encephalopathy, branch retinal artery occlusions
(BRAO) and hearing loss.1–3 An inflammatory or vascular
background, or both, for this small vessel disease is
controversially discussed. Therapeutic options are rare.
A 17-year-old girl without a remarkable medical history
presented with several episodes of acute psychosis, nausea,
dysarthria, ataxia, visual field defects, asymmetrical hearing
loss and prodromal migrainous headache. Fluorescence
angiography showed branch retinal artery occlusions (fig 1).
Audiometry showed sensorineural pancochlear bilateral
hypacusis. Magnetic resonance imaging showed hyperintense
snowball-like lesions of the corpus callosum (fig 2).4 These
clinical investigations confirmed the diagnosis of Susac’s
syndrome. Risk factors such as smoking, reduced protein S
activity, oral contraception and prodromal viral infection of
the respiratory tract were found. Treatment with high-dose
glucocorticoids during the acute episodes, and a secondary
prophylactic treatment with nimodipine and aspirin, was
effective in both reducing the severity of acute symptoms and
preventing further episodes.5
From the presented case, we conclude that (1) the triad of
encephalopathy, branch retinal artery occlusions and sudden
hearing loss in young women strongly suggests Susac’s
syndrome; (2) snowball-shaped lesions in the corpus callosum
appear highly specific for the clinical diagnosis of Susac’s
syndrome; and (3) the use of high-dose glucocorticoids in the
acute phase of the disease and prophylactic treatment with
aspirin and nimodipine seem to be beneficial for these patients,
but has to be evaluated prospectively in larger studies.
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Figure 1 Hyperfluorescent retinal arterial wall plaques, branch retinal
arterial occlusion and retrograde vessel filling. Arrows indicate leakage
of retinal arteries.
Figure 2 Sagittal T2-weighted image (fluid-attenuated inversion
recovery) showing multiple microinfarctions in the corpus callosum. Note
the ring-shaped lesion in the rostral genu, possibly representing a
residual snowball lesion (indicated by an arrow).
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